Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting

Asthma Clinical Trial

Official title:

An Open Label, Multi-centre, Post Marketing Surveillance to Observe the Safety and Effectiveness of ARNUITY Administered in Patients With Asthma in Usual Practice

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03595930
• Other study ID #: 207435
• Status: Completed
• Start date: September 21, 2018
• Est. completion date: July 22, 2020

Study information

• Verified date: August 2020
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This is an open-label, multi-center, PMS study to observe the safety and effectiveness of ARNUITY administered in asthma subjects in a real world setting. This PMS shall observe how a broad range of subjects use the drug in the early stages after obtaining the approval. The objective of this PMS is to collect safety and effectiveness data on ARNUITY's approved label in a real world setting. Total of 600 subjects shall be recruited throughout the PMS period; 01 Sep, 2018 to 30 June 2020. ARNUITY is the registered trademark of GSK group of companies.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 668
• Est. completion date: July 22, 2020
• Est. primary completion date: July 22, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Pediatric subjects older than 12 years of age and adult subjects with asthma

• Subjects who will administer ARNUITY in accordance with the product information approved in Korea

• Subjects who have signed the informed consent form for the PMS

Exclusion Criteria:

• Subjects with status asthmaticus or subjects who have administered ARNUITY as primary therapy for other acute asthmatic episodes that require intensive treatment

• Subjects who have any known hyper-sensitivity to the drug or its ingredients

• Subjects who have severe hypersensitive reactions to milk proteins

• Subjects with hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption

Related Conditions & MeSH terms

• Asthma

Intervention

Drug:
• Arnuity
ARNUITY consist of Fluticasone Furoate, is an Inhaled corticosteroids (ICS) medicine taken as one inhalation, once daily, for the control and prevention of asthma in adults and children aged 12 years and older.

Locations

Country	Name	City	State
Korea, Republic of	GSK Investigational Site	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence rate of adverse events (AEs) after ARNUITY administration	An AE is defined as any undesirable, unintended signs (e.g., abnormal laboratory findings), symptoms, or disease that may occur after administration or during use of the product, and does not necessarily have to have a causal relationship with the product.	Up to 22months
Primary	Incidence rates of unexpected AEs and adverse drug reactions (ADRs)	An ADR is defined as an adverse event whose causal relationship with the product cannot be ruled out.	Up to 22 months
Primary	Incidence rates of serious AEs (SAEs) and serious ADRs (SADRs)	A SAE refers to any one of the following adverse events, which: results in death or is life-threatening; results in or prolongs hospitalization; results in persistent or serious disability or incapacity; results in a birth defect or anomaly; or is an important medical event. SADR is defined a SAE whose causal relationship with the product cannot be ruled out.	Up to 22 months
Primary	Number of subjects with abnormal findings as assessed by physician's effectiveness assessment	For the subjective assessment of effectiveness, the physicians shall assess physician's effectiveness assessment at Week 24 after administration of Arnuity, based on the pulmonary function test and/or asthma symptom control.	Week 24
Primary	Change in Forced Expiratory Volume in 1 Second (FEV1) before and after ARNUITY administration	The physicians shall collect FEV1 data at Week 0 and Week 24 after Arnuity administration. The change in the FEV1 results before and after administration of the product shall be analyzed using a paired t-test.	Week 0, Week 24
Primary	Change in Forced Vital Capacity (FVC) before and after ARNUITY administration	The physicians shall collect FVC data at Week 0 and Week 24 after Arnuity administration. The change in the FVC results before and after administration of the product shall be analyzed using a paired t-test.	Week 0, Week 24
Primary	Change in FEV1/FVC ratio before and after ARNUITY administration	The physicians shall collect FEV1/FVC data at Week 0 and Week 24 after Arnuity administration. The change in the FEV1/ FVC ratio before and after administration of the product shall be analyzed using a paired t-test	Week 0, Week 24
Primary	Changes in the asthma symptom control results before and after ARNUITY administration	The physician shall collect the asthma symptom control results at Week 0 and Week 24 after Arnuity administration, based on the symptoms the subjects experienced for the past 4 weeks. The results of the asthma symptom control shall be categorized into 'Controlled', 'Partly Controlled', and 'Uncontrolled'.	Week 0, Week 24